MBX Biosciences Announces Last Subject Last Visit in Phase 1 Trial of MBX 1416 for the Treatment of Post-Bariatric Hypoglycemia
November 18, 2024 08:00 ET
|
MBX Biosciences, Inc.
CARMEL, Ind., Nov. 18, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide...
MBX Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update
November 07, 2024 08:00 ET
|
MBX Biosciences, Inc.
Total gross proceeds from upsized initial public offering and Series C financing were approximately $251.2 million Last subject last visit in Phase 1 trial of MBX 1416 anticipated by late November;...
MBX Biosciences to Participate in Upcoming November Investor Conferences
October 28, 2024 08:00 ET
|
MBX Biosciences, Inc.
CARMEL, Ind., Oct. 28, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide...
MBX Biosciences Presents MBX 2109 Phase 2 Avail™ Hypoparathyroidism Trial Rationale and Design at the ASBMR 2024 Annual Meeting
September 30, 2024 08:00 ET
|
MBX Biosciences, Inc.
CARMEL, Ind., Sept. 30, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (NASDAQ: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide...
MBX Biosciences Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
September 16, 2024 16:05 ET
|
MBX Biosciences, Inc.
CARMEL, Ind., Sept. 16, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX) (“MBX Biosciences”), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...
MBX Biosciences Announces Pricing of Initial Public Offering
September 12, 2024 19:11 ET
|
MBX Biosciences, Inc.
CARMEL, Ind., Sept. 12, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX) (“MBX Biosciences”), a clinical-stage biopharmaceutical company focused on the discovery and development of novel...
MBX Biosciences Announces Launch of Initial Public Offering
September 09, 2024 06:30 ET
|
MBX Biosciences, Inc.
CARMEL, Ind., Sept. 09, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (“MBX Biosciences”), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision...
MBX Biosciences Doses First Patient in Phase 2 Avail™ Trial of MBX 2109 for the Treatment of Hypoparathyroidism
August 12, 2024 08:00 ET
|
MBX Biosciences, Inc.
CARMEL, Ind., Aug. 12, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for...
MBX Biosciences Raises $63.5 Million in Series C Financing to Advance Precision Endocrine Peptide™ (PEP™) Platform
August 05, 2024 08:00 ET
|
MBX Biosciences, Inc.
Financing led by Deep Track Capital, with new investments from Driehaus Capital Management and funds and accounts advised by T. Rowe Price Associates, Inc. Proceeds to support ongoing Phase 2...
MBX Biosciences Appoints Salomon Azoulay, M.D., as Chief Medical Officer
June 25, 2024 08:00 ET
|
MBX Biosciences, Inc.
CARMEL, Ind., June 25, 2024 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for...